Trial watch: dendritic cell vaccination for cancer immunotherapy

Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D. Garg

doi:10.1080/2162402X.2019.1638212

Trial watch: dendritic cell vaccination for cancer immunotherapy

Jenny Sprooten, Jolien Ceusters, An Coosemans, Patrizia Agostinis, Steven De Vleeschouwer, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi, Abhishek D. Garg

Research output: Contribution to journal › Review article › peer-review

117 Citations (Scopus)

Abstract

Dendritic- cells (DCs) have received considerable attention as potential targets for the development of anticancer vaccines. DC-based anticancer vaccination relies on patient-derived DCs pulsed with a source of tumor-associated antigens (TAAs) in the context of standardized maturation-cocktails, followed by their reinfusion. Extensive evidence has confirmed that DC-based vaccines can generate TAA-specific, cytotoxic T cells. Nonetheless, clinical efficacy of DC-based vaccines remains suboptimal, reflecting the widespread immunosuppression within tumors. Thus, clinical interest is being refocused on DC-based vaccines as combinatorial partners for T cell-targeting immunotherapies. Here, we summarize the most recent preclinical/clinical development of anticancer DC vaccination and discuss future perspectives for DC-based vaccines in immuno-oncology.

Original language	English
Article number	e1638212
Journal	OncoImmunology
Volume	8
Issue number	11
DOIs	https://doi.org/10.1080/2162402X.2019.1638212
Publication status	Published - 2 Nov 2019

Keywords

Antigen cross-presentation
DAMPs
TLR signaling
clinical trial
immune checkpoint blockers
plasmacytoid dendritic cells
tumor-infiltrating lymphocytes

Access to Document

10.1080/2162402X.2019.1638212

Cite this

@article{3db73f52089143b89789fd3001e93be4,

title = "Trial watch: dendritic cell vaccination for cancer immunotherapy",

abstract = "Dendritic- cells (DCs) have received considerable attention as potential targets for the development of anticancer vaccines. DC-based anticancer vaccination relies on patient-derived DCs pulsed with a source of tumor-associated antigens (TAAs) in the context of standardized maturation-cocktails, followed by their reinfusion. Extensive evidence has confirmed that DC-based vaccines can generate TAA-specific, cytotoxic T cells. Nonetheless, clinical efficacy of DC-based vaccines remains suboptimal, reflecting the widespread immunosuppression within tumors. Thus, clinical interest is being refocused on DC-based vaccines as combinatorial partners for T cell-targeting immunotherapies. Here, we summarize the most recent preclinical/clinical development of anticancer DC vaccination and discuss future perspectives for DC-based vaccines in immuno-oncology.",

keywords = "Antigen cross-presentation, DAMPs, TLR signaling, clinical trial, immune checkpoint blockers, plasmacytoid dendritic cells, tumor-infiltrating lymphocytes",

author = "Jenny Sprooten and Jolien Ceusters and An Coosemans and Patrizia Agostinis and {De Vleeschouwer}, Steven and Laurence Zitvogel and Guido Kroemer and Lorenzo Galluzzi and Garg, {Abhishek D.}",

note = "Publisher Copyright: {\textcopyright} 2019, {\textcopyright} 2019 Taylor & Francis Group, LLC.",

year = "2019",

month = nov,

day = "2",

doi = "10.1080/2162402X.2019.1638212",

language = "English",

volume = "8",

journal = "OncoImmunology",

issn = "2162-4011",

number = "11",

}

TY - JOUR

T1 - Trial watch

T2 - dendritic cell vaccination for cancer immunotherapy

AU - Sprooten, Jenny

AU - Ceusters, Jolien

AU - Coosemans, An

AU - Agostinis, Patrizia

AU - De Vleeschouwer, Steven

AU - Zitvogel, Laurence

AU - Kroemer, Guido

AU - Galluzzi, Lorenzo

AU - Garg, Abhishek D.

PY - 2019/11/2

Y1 - 2019/11/2

N2 - Dendritic- cells (DCs) have received considerable attention as potential targets for the development of anticancer vaccines. DC-based anticancer vaccination relies on patient-derived DCs pulsed with a source of tumor-associated antigens (TAAs) in the context of standardized maturation-cocktails, followed by their reinfusion. Extensive evidence has confirmed that DC-based vaccines can generate TAA-specific, cytotoxic T cells. Nonetheless, clinical efficacy of DC-based vaccines remains suboptimal, reflecting the widespread immunosuppression within tumors. Thus, clinical interest is being refocused on DC-based vaccines as combinatorial partners for T cell-targeting immunotherapies. Here, we summarize the most recent preclinical/clinical development of anticancer DC vaccination and discuss future perspectives for DC-based vaccines in immuno-oncology.

AB - Dendritic- cells (DCs) have received considerable attention as potential targets for the development of anticancer vaccines. DC-based anticancer vaccination relies on patient-derived DCs pulsed with a source of tumor-associated antigens (TAAs) in the context of standardized maturation-cocktails, followed by their reinfusion. Extensive evidence has confirmed that DC-based vaccines can generate TAA-specific, cytotoxic T cells. Nonetheless, clinical efficacy of DC-based vaccines remains suboptimal, reflecting the widespread immunosuppression within tumors. Thus, clinical interest is being refocused on DC-based vaccines as combinatorial partners for T cell-targeting immunotherapies. Here, we summarize the most recent preclinical/clinical development of anticancer DC vaccination and discuss future perspectives for DC-based vaccines in immuno-oncology.

KW - Antigen cross-presentation

KW - DAMPs

KW - TLR signaling

KW - clinical trial

KW - immune checkpoint blockers

KW - plasmacytoid dendritic cells

KW - tumor-infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=85072034344&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2019.1638212

DO - 10.1080/2162402X.2019.1638212

M3 - Review article

C2 - 31646087

AN - SCOPUS:85072034344

SN - 2162-4011

VL - 8

JO - OncoImmunology

JF - OncoImmunology

IS - 11

M1 - e1638212

ER -

Trial watch: dendritic cell vaccination for cancer immunotherapy

Abstract

Keywords

Access to Document

Other files and links

Cite this